Naoaki Sakata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naoaki Sakata has a total of 534 co-authors. Here are the top co-authors by number of shared publications:
Michiaki Unno
Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
49 shared publications- Shinichi Egawa
Tohoku University
45 shared publications Fuyuhiko Motoi
Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
36 shared publications- Takeshi Naitoh
Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan
34 shared publications Yu Katayose
Division of Gastroenterological Surgery, Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan; Division of Integrated Surgery and Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
33 shared publicationsGumpei Yoshimatsu
Department of Regenerative Medicine and Transplantation Faculty of Medicine Fukuoka University Jonanāku Fukuoka Japan
31 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published byĀ American Society of HematologyĀ inĀ Blood Advances
- Vol.Ā 10 Ā (16) , 5531-5542
WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study
This phase II clinical study evaluated the efficacy and safety of post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) maintenance cancer immunotherapy using two WT1 peptide vaccines-MCI-for pediatric refractory acute leukemias. Each of 17 patients (median age, 8.3 years; age range, 2-18 years) was intradermally injected with either of the vaccines. The 3-year overall survival (OS) rate-the primary endpoint-was 70.6% [95% confidence interval (CI), 43.1-86.6%]; this rate was higher than 30%, a historical control benchmark, and was attributable to the fact that 12 clinical responders-who sustained complete remission at year 1 after the initiation of vaccination-had a high 3-year OS rate of 91.7% (95% CI, 53.9-98.7%). WT1-specific cytotoxic T cell (CTL) frequency in peripheral blood (PB) from all of 12 clinical responders increased significantly after vaccination, reaching the maximum by week 12 of vaccination (before, 0.25±0.08%; after, 1.07±0.24%; P <.001), while WT1-specific CTL frequency in PB from clinical nonresponders remained unchanged after vaccination (before, 0.12±0.2%; after, 0.20±0.25%; P=.424). The estimated 3-year OS rate was significantly higher for 11 immune responders (who showed a ³1.455-fold increase from the baseline value: 90.9%) than for 5 immune nonresponders (40.0%; P=.027). Elevated WT1-specific CTL frequency in PB before vaccination predicted the subsequent favorable prognosis of all patients. No patients discontinued treatment due to MCI. Adverse events including graft-versus-host disease were manageable. MCI was suggested to be very effective and safe for pediatric patients with refractory acute leukemias, indicating its potential to improve their survival through relapse prevention. UMIN000005319
- 16 June 2026
- Published byĀ American Society of HematologyĀ inĀ Blood Advances
- Vol.Ā 10 Ā (16) , 5531-5542
Open AccessWT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study
This phase II clinical study evaluated the efficacy and safety of post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) maintenance cancer immunotherapy using two WT1 peptide vaccines-MCI-for pediatric refractory acute leukemias. Each of 17 patients (median age, 8.3 years; age range, 2-18 years) was intradermally injected with either of the vaccines. The 3-year overall survival (OS) rate-the primary endpoint-was 70.6% [95% confidence interval (CI), 43.1-86.6%]; this rate was higher than 30%, a historical control benchmark, and was attributable to the fact that 12 clinical responders-who sustained complete remission at year 1 after the initiation of vaccination-had a high 3-year OS rate of 91.7% (95% CI, 53.9-98.7%). WT1-specific cytotoxic T cell (CTL) frequency in peripheral blood (PB) from all of 12 clinical responders increased significantly after vaccination, reaching the maximum by week 12 of vaccination (before, 0.25±0.08%; after, 1.07±0.24%; P <.001), while WT1-specific CTL frequency in PB from clinical nonresponders remained unchanged after vaccination (before, 0.12±0.2%; after, 0.20±0.25%; P=.424). The estimated 3-year OS rate was significantly higher for 11 immune responders (who showed a ³1.455-fold increase from the baseline value: 90.9%) than for 5 immune nonresponders (40.0%; P=.027). Elevated WT1-specific CTL frequency in PB before vaccination predicted the subsequent favorable prognosis of all patients. No patients discontinued treatment due to MCI. Adverse events including graft-versus-host disease were manageable. MCI was suggested to be very effective and safe for pediatric patients with refractory acute leukemias, indicating its potential to improve their survival through relapse prevention. UMIN000005319
- Open Access
The Japanese Macaque as a Diabetes Recipient Animal Model for Porcine Islet Xenotransplantation
Porcine islet xenotransplantation is effective for severe diabetes; however, preclinical studies are essential. In this study, we evaluated the suitability of the Japanese macaque as a recipient model for islet xenotransplantation, including identifying the preferred method to induce diabetes. The safety and stability of the following four models to induce diabetes were assessed: Model 1: pancreatectomy, Model 2: pancreatectomy with lowādose streptozotocin (STZ), Model 3: singleāinjection of STZ, and Model 4: consecutive administrations of lowādose STZ. Diabetes was induced in all four models. The blood glucose level after induction of diabetes was 225.32 ± 46.49 mg/dL in Model 1, 209.64 ± 64.36 mg/dL in Model 2, 175.51 ± 45.18 mg/dL in Model 3, and 139.22 ± 6.31 mg/dL in Model 4. Regarding safety, Models 1 and 2 involved invasive surgery with postoperative concerns. Model 3 induced diabetes in the Japanese macaques; however, the preferable dose of STZ was individual dependent. Among the models, Model 4 was preferable regarding safety and stability. Finally, we performed porcine islet xenotransplantation in a diabetic monkey in Model 4 and evaluated the therapeutic effects of this treatment. In conclusion, the Japanese macaque might be a possible recipient model for porcine islet xenotransplantation.
Open AccessThe Japanese Macaque as a Diabetes Recipient Animal Model for Porcine Islet Xenotransplantation
Porcine islet xenotransplantation is effective for severe diabetes; however, preclinical studies are essential. In this study, we evaluated the suitability of the Japanese macaque as a recipient model for islet xenotransplantation, including identifying the preferred method to induce diabetes. The safety and stability of the following four models to induce diabetes were assessed: Model 1: pancreatectomy, Model 2: pancreatectomy with lowādose streptozotocin (STZ), Model 3: singleāinjection of STZ, and Model 4: consecutive administrations of lowādose STZ. Diabetes was induced in all four models. The blood glucose level after induction of diabetes was 225.32 ± 46.49 mg/dL in Model 1, 209.64 ± 64.36 mg/dL in Model 2, 175.51 ± 45.18 mg/dL in Model 3, and 139.22 ± 6.31 mg/dL in Model 4. Regarding safety, Models 1 and 2 involved invasive surgery with postoperative concerns. Model 3 induced diabetes in the Japanese macaques; however, the preferable dose of STZ was individual dependent. Among the models, Model 4 was preferable regarding safety and stability. Finally, we performed porcine islet xenotransplantation in a diabetic monkey in Model 4 and evaluated the therapeutic effects of this treatment. In conclusion, the Japanese macaque might be a possible recipient model for porcine islet xenotransplantation.
- Open Access
- 12 March 2026
- Published byĀ Rockefeller University PressĀ inĀ Journal of Human Immunity
- Vol.Ā 2 Ā (3)
Polyclonal evolution of lymphoproliferative disorders in XLP1
X-linked lymphoproliferative syndrome type 1 (XLP1) is an inborn error of immunity caused by pathogenic variants in SH2D1A and is frequently complicated by Epstein-Barr virus (EBV)āassociated lymphoproliferative disorders (LPDs). However, cases of LPD without EBV infection have been reported and remain poorly understood. We investigated tumorigenesis mechanisms through transcriptomic profiling and somatic variant analysis in tumor samples from six patients with XLP1. Pathogenic variants were identified in two: one developed two distinct LPDs harboring CARD11/GNA13 and MECOM variants, while the other carried IRF4, P2RY8, KRAS, and CCND3 variants. Transcriptome analysis of three tumors, compared with diffuse large B cell lymphoma from patients without an underlying immune defect, revealed a distinct expression profile. Gene Ontology analysis showed upregulation of adaptive immune response genes, including various IgH and TCR genes, suggesting polyclonal lymphocyte proliferation. Overall, LPD associated with XLP1 may originate from polyclonal lymphocyte expansion, either in the presence or absence of EBV infection, and subsequently progress to malignancy through somatic variants.
- 12 March 2026
- Published byĀ Rockefeller University PressĀ inĀ Journal of Human Immunity
- Vol.Ā 2 Ā (3)
Open AccessPolyclonal evolution of lymphoproliferative disorders in XLP1
X-linked lymphoproliferative syndrome type 1 (XLP1) is an inborn error of immunity caused by pathogenic variants in SH2D1A and is frequently complicated by Epstein-Barr virus (EBV)āassociated lymphoproliferative disorders (LPDs). However, cases of LPD without EBV infection have been reported and remain poorly understood. We investigated tumorigenesis mechanisms through transcriptomic profiling and somatic variant analysis in tumor samples from six patients with XLP1. Pathogenic variants were identified in two: one developed two distinct LPDs harboring CARD11/GNA13 and MECOM variants, while the other carried IRF4, P2RY8, KRAS, and CCND3 variants. Transcriptome analysis of three tumors, compared with diffuse large B cell lymphoma from patients without an underlying immune defect, revealed a distinct expression profile. Gene Ontology analysis showed upregulation of adaptive immune response genes, including various IgH and TCR genes, suggesting polyclonal lymphocyte proliferation. Overall, LPD associated with XLP1 may originate from polyclonal lymphocyte expansion, either in the presence or absence of EBV infection, and subsequently progress to malignancy through somatic variants.
- Open Access
- 22 January 2026
- Published byĀ SAGE PublicationsĀ inĀ Cell Transplantation
- Vol.Ā 35
Editorial: Cellular replacement therapy for diabetes
Diabetes mellitus (DM) is a metabolic disorder with chronic hyperglycemia due to insulin deficiency and/or impaired insulin action. DM is a common disease, but it often threatens a patientās quality of life. Cellular replacement therapy using insulin-producing cells is a promising therapy for severe DM because of the proper provision of internal insulin according to a change in blood glucose concentrations. This Special Collection, āCellular Replacement Therapy for Diabetes,ā was planned to appeal the current status and present novel translational trials of this therapy. Ten specialists presented their research, which attempted to overcome three limitations of the current cellular replacement therapy, including the regulation of immunity, limited donor supplies, and establishment of a preferable transplant site for cellular replacement therapy. Regarding regulation of immunity, potential of mesenchymal stem cells and immunomodulatory splenocytes is clarified. Regarding alternative donors, the current status of porcine islet xenotransplantation and therapy using multipotent stem cellāderived cells is introduced. And regarding transplant site, possibility of liver surface and subcutaneous tissue is elucidated.
- 22 January 2026
- Published byĀ SAGE PublicationsĀ inĀ Cell Transplantation
- Vol.Ā 35
Open AccessEditorial: Cellular replacement therapy for diabetes
Diabetes mellitus (DM) is a metabolic disorder with chronic hyperglycemia due to insulin deficiency and/or impaired insulin action. DM is a common disease, but it often threatens a patientās quality of life. Cellular replacement therapy using insulin-producing cells is a promising therapy for severe DM because of the proper provision of internal insulin according to a change in blood glucose concentrations. This Special Collection, āCellular Replacement Therapy for Diabetes,ā was planned to appeal the current status and present novel translational trials of this therapy. Ten specialists presented their research, which attempted to overcome three limitations of the current cellular replacement therapy, including the regulation of immunity, limited donor supplies, and establishment of a preferable transplant site for cellular replacement therapy. Regarding regulation of immunity, potential of mesenchymal stem cells and immunomodulatory splenocytes is clarified. Regarding alternative donors, the current status of porcine islet xenotransplantation and therapy using multipotent stem cellāderived cells is introduced. And regarding transplant site, possibility of liver surface and subcutaneous tissue is elucidated.
- Open Access
- 13 March 2025
- Published byĀ SAGE PublicationsĀ inĀ Cell Transplantation
- Vol.Ā 34
Safe Administration of Immunosuppression in Japanese Monkeys: Relevance to Preclinical Xenotransplantation Studies
The Japanese monkey has been used in several animal studies; however, its potential as a recipient model for xenotransplantation is unclear. The potential of the Japanese monkey as a recipient for xenotransplantation was assessed using two experimental models. The first model evaluated the optimal dose of tacrolimus without severe adverse events. The plasma tacrolimus levels, blood counts, and hepatic and renal function tests were evaluated. The second model assessed the immunosuppressive effects of thymoglobulin and tacrolimus. Immunosuppression was evaluated using blood counts and flow cytometry to measure lymphocytes in peripheral blood mononuclear cells (PBMCs). In the first model, the target trough level (10ā15 ng/ml) was achieved and maintained with tacrolimus administration at 1.6 mg/kg/day in all monkeys. There were no adverse events related to the blood count or to liver, kidney, or nutrient parameters at this dose, except for hemoglobin. In the second model, a decrease in white blood cells was observed. Flow cytometry revealed a temporary decrease in T- and B-cell numbers among PBMCs on day 4. We consider that the Japanese monkey is acceptable to be used as a recipient model for preclinical xenotransplantation. The safe administration of tacrolimus and thymoglobulin is clarified for this model.
- 13 March 2025
- Published byĀ SAGE PublicationsĀ inĀ Cell Transplantation
- Vol.Ā 34
Open AccessSafe Administration of Immunosuppression in Japanese Monkeys: Relevance to Preclinical Xenotransplantation Studies
The Japanese monkey has been used in several animal studies; however, its potential as a recipient model for xenotransplantation is unclear. The potential of the Japanese monkey as a recipient for xenotransplantation was assessed using two experimental models. The first model evaluated the optimal dose of tacrolimus without severe adverse events. The plasma tacrolimus levels, blood counts, and hepatic and renal function tests were evaluated. The second model assessed the immunosuppressive effects of thymoglobulin and tacrolimus. Immunosuppression was evaluated using blood counts and flow cytometry to measure lymphocytes in peripheral blood mononuclear cells (PBMCs). In the first model, the target trough level (10ā15 ng/ml) was achieved and maintained with tacrolimus administration at 1.6 mg/kg/day in all monkeys. There were no adverse events related to the blood count or to liver, kidney, or nutrient parameters at this dose, except for hemoglobin. In the second model, a decrease in white blood cells was observed. Flow cytometry revealed a temporary decrease in T- and B-cell numbers among PBMCs on day 4. We consider that the Japanese monkey is acceptable to be used as a recipient model for preclinical xenotransplantation. The safe administration of tacrolimus and thymoglobulin is clarified for this model.
- Open Access
- 1 September 2024
- Published byĀ Wolters Kluwer HealthĀ inĀ Plastic and Reconstructive Surgery - Global Open
- Vol.Ā 12 Ā (9) , e6200
Effectiveness Evaluation of Microneedling Therapy for Diabetic Ulcer: An Animal Model Study
Background: Diabetic ulcer is an intractable complication seen in nearly 6% of diabetes patients. Some patients with diabetic ulcers cannot avoid femoral amputation by the current standard treatments. Therefore, a novel and effective radical cure therapy is needed. Microneedling is a widely applied wound-healing treatment in cosmetic medicine. In this study, we evaluated the therapeutic effects of microneedling on diabetic ulcers using an animal model. Methods: Nine- to 10-week-old male C57BL/6J mice with drug-induced diabetes received full-thickness skin removal on the back. The mice with and without microneedling were classified into microneedling and nontreatment groups, respectively. The therapeutic effects of microneedling were assessed by wound closure rate by 14 days after the treatment and histological assessments in the wound. Results: The wound closure rate was significantly higher in the microneedling group than in the nontreatment groups from 7 days after microneedling (wound closure rate: 63.0 ± 10.2% versus 36.6 ± 12.1%). Histological assessments revealed that microneedling induced infiltration of neutrophils and M1 macrophages into the microhemorrhage region within 12 hours. The macrophages shifted to M2 macrophages 4 days after microneedling. Hyperexpression of transforming growth factor beta 1 was confirmed 7 days after microneedling. After that, the promotion of collagen proliferation and neovascularization were seen 10 and 14 days after microneedling, respectively. Conclusions: Our data clarified that microneedling was effective for wound healing in an animal model of diabetic ulcer. This study has limitations correlated with small animal models and acute surgical wounds. Future clinical trials are recommended.
- 1 September 2024
- Published byĀ Wolters Kluwer HealthĀ inĀ Plastic and Reconstructive Surgery - Global Open
- Vol.Ā 12 Ā (9) , e6200
Open AccessEffectiveness Evaluation of Microneedling Therapy for Diabetic Ulcer: An Animal Model Study
Background: Diabetic ulcer is an intractable complication seen in nearly 6% of diabetes patients. Some patients with diabetic ulcers cannot avoid femoral amputation by the current standard treatments. Therefore, a novel and effective radical cure therapy is needed. Microneedling is a widely applied wound-healing treatment in cosmetic medicine. In this study, we evaluated the therapeutic effects of microneedling on diabetic ulcers using an animal model. Methods: Nine- to 10-week-old male C57BL/6J mice with drug-induced diabetes received full-thickness skin removal on the back. The mice with and without microneedling were classified into microneedling and nontreatment groups, respectively. The therapeutic effects of microneedling were assessed by wound closure rate by 14 days after the treatment and histological assessments in the wound. Results: The wound closure rate was significantly higher in the microneedling group than in the nontreatment groups from 7 days after microneedling (wound closure rate: 63.0 ± 10.2% versus 36.6 ± 12.1%). Histological assessments revealed that microneedling induced infiltration of neutrophils and M1 macrophages into the microhemorrhage region within 12 hours. The macrophages shifted to M2 macrophages 4 days after microneedling. Hyperexpression of transforming growth factor beta 1 was confirmed 7 days after microneedling. After that, the promotion of collagen proliferation and neovascularization were seen 10 and 14 days after microneedling, respectively. Conclusions: Our data clarified that microneedling was effective for wound healing in an animal model of diabetic ulcer. This study has limitations correlated with small animal models and acute surgical wounds. Future clinical trials are recommended.
- Open Access
- 21 May 2024
- Published byĀ Springer NatureĀ inĀ Scientific Reports
- Vol.Ā 14 Ā (1) , 1-11
Influence of relatively short-term culture on adult porcine islets for xenotransplantation
Porcine islet xenotransplantation is a promising therapy for severe diabetes mellitus. Maintenance of the quality and quantity of porcine islets is important for the success of this treatment. Here, we aimed to elucidate the influence of relatively short-term (14 days) culture on adult porcine islets isolated from three micro-minipigs (P111, P112 and P121). Morphological characteristics of islets changed little after 14 days of culture. The viability of cultured islets was also maintained at a high level (> 80%). Furthermore, cultured islets exhibited similar glucose-stimulated insulin secretion and insulin content at Day 14 were preserved comparing with Day 1, while the expressions of Ins, Gcg and Sst were attenuated at Day 14. Xenotransplantation using diabetic nude mice showed no normalization of blood glucose but increased levels of plasma porcine C-peptide after the transplantation of 14 day cultured porcine islets. Histological assessment revealed that relatively short-term cultured porcine islets were successfully engrafted 56 days following transplantation. These data show that relatively short-term culture did not impair the quality of adult porcine islets in regard to function, morphology, and viability. Prevention of impairment of gene correlated with endocrine hormone is warranted for further improvement.
- 21 May 2024
- Published byĀ Springer NatureĀ inĀ Scientific Reports
- Vol.Ā 14 Ā (1) , 1-11
Open AccessInfluence of relatively short-term culture on adult porcine islets for xenotransplantation
Porcine islet xenotransplantation is a promising therapy for severe diabetes mellitus. Maintenance of the quality and quantity of porcine islets is important for the success of this treatment. Here, we aimed to elucidate the influence of relatively short-term (14 days) culture on adult porcine islets isolated from three micro-minipigs (P111, P112 and P121). Morphological characteristics of islets changed little after 14 days of culture. The viability of cultured islets was also maintained at a high level (> 80%). Furthermore, cultured islets exhibited similar glucose-stimulated insulin secretion and insulin content at Day 14 were preserved comparing with Day 1, while the expressions of Ins, Gcg and Sst were attenuated at Day 14. Xenotransplantation using diabetic nude mice showed no normalization of blood glucose but increased levels of plasma porcine C-peptide after the transplantation of 14 day cultured porcine islets. Histological assessment revealed that relatively short-term cultured porcine islets were successfully engrafted 56 days following transplantation. These data show that relatively short-term culture did not impair the quality of adult porcine islets in regard to function, morphology, and viability. Prevention of impairment of gene correlated with endocrine hormone is warranted for further improvement.
- Open Access
- 16 March 2024
- Published byĀ Springer NatureĀ inĀ Scientific Reports
- Vol.Ā 14 Ā (1) , 1-16
The porcine islet-derived organoid showed the characteristics as pancreatic duct
Organoid is a tissue-engineered organ-like structure that resemble as an organ. Porcine islet-derived organoid might be used as an alternative donor of porcine islet xenotransplantation, a promising therapy for severe diabetes. In this study, we elucidated the characteristics of porcine islet organoids derived from porcine islets as a cell source for transplantation. Isolated porcine islets were 3D-cultured using growth factor-reduced matrigel in organoid culture medium consist of advanced DMEM/F12 with Wnt-3A, R-spondin, EGF, Noggin, IGF-1, bFGF, nicotinamide, B27, and some small molecules. Morphological and functional characteristics of islet organoids were evaluated in comparison with 2D-cultured islets in advanced DMEM/F12 medium. Relatively short-term (approximately 14 days)ācultured porcine islet organoids were enlarged and proliferated, but had an attenuated insulin-releasing function. Long-term (over a month)ācultured islet organoids could be passaged and cryopreserved. However, they showed pancreatic duct characteristics, including cystic induction, strong expression of Sox9, loss of PDX1 expression, and no insulin-releasing function. These findings were seen in long-term-cultured porcine islets. In conclusion, our porcine islet organoids showed the characteristics of pancreatic ducts. Further study is necessary for producing porcine islet-derived organoids having characteristics as islets.
- 16 March 2024
- Published byĀ Springer NatureĀ inĀ Scientific Reports
- Vol.Ā 14 Ā (1) , 1-16
Open AccessThe porcine islet-derived organoid showed the characteristics as pancreatic duct
Organoid is a tissue-engineered organ-like structure that resemble as an organ. Porcine islet-derived organoid might be used as an alternative donor of porcine islet xenotransplantation, a promising therapy for severe diabetes. In this study, we elucidated the characteristics of porcine islet organoids derived from porcine islets as a cell source for transplantation. Isolated porcine islets were 3D-cultured using growth factor-reduced matrigel in organoid culture medium consist of advanced DMEM/F12 with Wnt-3A, R-spondin, EGF, Noggin, IGF-1, bFGF, nicotinamide, B27, and some small molecules. Morphological and functional characteristics of islet organoids were evaluated in comparison with 2D-cultured islets in advanced DMEM/F12 medium. Relatively short-term (approximately 14 days)ācultured porcine islet organoids were enlarged and proliferated, but had an attenuated insulin-releasing function. Long-term (over a month)ācultured islet organoids could be passaged and cryopreserved. However, they showed pancreatic duct characteristics, including cystic induction, strong expression of Sox9, loss of PDX1 expression, and no insulin-releasing function. These findings were seen in long-term-cultured porcine islets. In conclusion, our porcine islet organoids showed the characteristics of pancreatic ducts. Further study is necessary for producing porcine islet-derived organoids having characteristics as islets.
- Open Access
- 1 January 2024
- Published byĀ SAGE PublicationsĀ inĀ Cell Transplantation
- Vol.Ā 33
Efficacy of Neonatal Porcine Bone MarrowāDerived Mesenchymal Stem Cell Xenotransplantation for the Therapy of Hind Limb Lymphedema in Mice
Lymphedema is an intractable disease with few effective therapeutic options. Autologous mesenchymal stem cell (MSC) transplantation is a promising therapy for this disease. However, its use is limited by the cost and time for preparation. Recently, xenotransplantation of porcine MSCs has emerged as an alternative to autologous MSC transplantation. In this study, we aimed to clarify the usefulness of neonatal porcine bone marrowāderived MSC (NpBM-MSC) xenotransplantation for the treatment of lymphedema. One million NpBM-MSCs were xenotransplanted into the hind limbs of mice with severe lymphedema (MSC transplantation group). The therapeutic effects were assessed by measuring the femoral circumference, the volume of the hind limb, the number and diameter of lymphatic vessels in the hind limb, and lymphatic flow using a near-infrared fluorescence (NIRF) imaging system. We compared the effects using mice with lymphedema that did not undergo NpBM-MSC transplantation (negative control group). The condition of the transplanted NpBM-MSCs was also evaluated histologically. The femoral circumference and volume of the hind limb had been normalized by postoperative day (POD) 14 in the MSC transplantation group, but not in the negative control group ( P = 0.041). NIRF imaging revealed that lymphatic flow had recovered in the MSC transplantation group by POD 14, as shown by an increase in luminance in the hind limb. Histological assessment also showed that the xenotransplantation of NpBM-MSC increased the proliferation of lymphatic vessels, but they had been rejected by POD 14. The xenotransplantation of NpBM-MSCs is an effective treatment for lymphedema, and this is mediated through the promotion of lymphangiogenesis.
- 1 January 2024
- Published byĀ SAGE PublicationsĀ inĀ Cell Transplantation
- Vol.Ā 33
Open AccessEfficacy of Neonatal Porcine Bone MarrowāDerived Mesenchymal Stem Cell Xenotransplantation for the Therapy of Hind Limb Lymphedema in Mice
Lymphedema is an intractable disease with few effective therapeutic options. Autologous mesenchymal stem cell (MSC) transplantation is a promising therapy for this disease. However, its use is limited by the cost and time for preparation. Recently, xenotransplantation of porcine MSCs has emerged as an alternative to autologous MSC transplantation. In this study, we aimed to clarify the usefulness of neonatal porcine bone marrowāderived MSC (NpBM-MSC) xenotransplantation for the treatment of lymphedema. One million NpBM-MSCs were xenotransplanted into the hind limbs of mice with severe lymphedema (MSC transplantation group). The therapeutic effects were assessed by measuring the femoral circumference, the volume of the hind limb, the number and diameter of lymphatic vessels in the hind limb, and lymphatic flow using a near-infrared fluorescence (NIRF) imaging system. We compared the effects using mice with lymphedema that did not undergo NpBM-MSC transplantation (negative control group). The condition of the transplanted NpBM-MSCs was also evaluated histologically. The femoral circumference and volume of the hind limb had been normalized by postoperative day (POD) 14 in the MSC transplantation group, but not in the negative control group ( P = 0.041). NIRF imaging revealed that lymphatic flow had recovered in the MSC transplantation group by POD 14, as shown by an increase in luminance in the hind limb. Histological assessment also showed that the xenotransplantation of NpBM-MSC increased the proliferation of lymphatic vessels, but they had been rejected by POD 14. The xenotransplantation of NpBM-MSCs is an effective treatment for lymphedema, and this is mediated through the promotion of lymphangiogenesis.
- Open Access
- 16 November 2023
- Published byĀ Springer NatureĀ inĀ Scientific Reports
- Vol.Ā 13 Ā (1) , 1-14
Rescue of murine hind limb ischemia via angiogenesis and lymphangiogenesis promoted by cellular communication network factor 2
Critical limb ischemia (CLI) is caused by severe arterial blockage with reduction of blood flow. The aim of this study was to determine whether therapeutic angiogenesis using cellular communication network factor 2 (CCN2) would be useful for treating CLI in an animal model. Recombinant CCN2 was administered intramuscularly to male C57BL/6J mice with hind limb ischemia. The therapeutic effect was evaluated by monitoring blood flow in the ischemic hind limb. In an in vivo assay, CCN2 restored blood flow in the ischemic hind limb by promoting both angiogenesis and lymphangiogenesis. VEGF-A and VEGF-C expression levels increased in the ischemic limb after treatment with CCN2. In an in vitro assay, CCN2 promoted proliferation of vascular and lymphatic endothelial cells, and it upregulated expression of Tgfb1 followed by expression of Vegfc and Vegfr3 in lymphatic endothelial cells under hypoxia. Suppression of Tgfb1 did not affect the activity of CCN2, activation of the TGF-β/SMAD signaling pathway, or expression of Vegfr3 in lymphatic endothelial cells. In summary, treatment using recombinant CCN2 could be a promising therapeutic strategy for CLI.
- 16 November 2023
- Published byĀ Springer NatureĀ inĀ Scientific Reports
- Vol.Ā 13 Ā (1) , 1-14
Open AccessRescue of murine hind limb ischemia via angiogenesis and lymphangiogenesis promoted by cellular communication network factor 2
Critical limb ischemia (CLI) is caused by severe arterial blockage with reduction of blood flow. The aim of this study was to determine whether therapeutic angiogenesis using cellular communication network factor 2 (CCN2) would be useful for treating CLI in an animal model. Recombinant CCN2 was administered intramuscularly to male C57BL/6J mice with hind limb ischemia. The therapeutic effect was evaluated by monitoring blood flow in the ischemic hind limb. In an in vivo assay, CCN2 restored blood flow in the ischemic hind limb by promoting both angiogenesis and lymphangiogenesis. VEGF-A and VEGF-C expression levels increased in the ischemic limb after treatment with CCN2. In an in vitro assay, CCN2 promoted proliferation of vascular and lymphatic endothelial cells, and it upregulated expression of Tgfb1 followed by expression of Vegfc and Vegfr3 in lymphatic endothelial cells under hypoxia. Suppression of Tgfb1 did not affect the activity of CCN2, activation of the TGF-β/SMAD signaling pathway, or expression of Vegfr3 in lymphatic endothelial cells. In summary, treatment using recombinant CCN2 could be a promising therapeutic strategy for CLI.